Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab With or Without Macular Laser for ME Secondary to BRVO
ChiCTR-IPR-17010568Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Feb 2017
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranibizumab in macular edema (2 arms), sponsored by Beijing Hospital. Primary endpoint: Best corrected visual acuity. Started Feb 2017; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on ChiCTR-IPR-17010568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010568.